Bedrijfsoverzicht
Assertio Holdings, Inc. operates as a pharmaceutical entity dedicated to delivering various therapeutic products to patients across the United States, with a specific focus on speciality and generic drug manufacturing. The company functions within the broader healthcare sector, specifically targeting the industry of drug manufacturers where it specializes in generic formulations like INDOCIN, an oral and suppository solution designed to treat moderate to severe rheumatoid arthritis, including acute flares of chronic disease and ankylosing spondylitis. In terms of scale, the organization maintains a market capitalization of $116.32 million and employs a workforce of 53 individuals to support its operations. These financial metrics indicate that Assertio Holdings positions itself as a mid-sized entity within the pharmaceutical landscape, possessing a market valuation that suggests a niche presence rather than mass-market dominance, while its annual revenue of $118.71 million reflects a specialized business model focused on specific indications rather than broad pharmaceutical portfolios.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $118.71 million, yet it simultaneously recorded a net income loss of $-30,375,000 and an EBITDA of $12.78 million, revealing a significant divergence between top-line sales and bottom-line profitability that highlights a challenging cost structure or high operating expenses relative to earnings. While the EBITDA remains positive at $12.78 million, the generation of free cash flow stands at $-16,582,250, indicating that the company is currently burning cash despite its earnings before interest, taxes, depreciation, and amortization, which constrains its immediate financial flexibility for capital expenditures or expansion without external financing. The margin analysis further elucidates this financial stress: the gross margin sits at 70.2%, suggesting efficient production costs, yet the operating margin is deeply negative at -105.2% and the profit margin is -25.6%, implying that general and administrative expenses, or R&D costs, are substantially outpacing the gross profits generated from sales. On the balance sheet, the firm holds $63.41 million in cash against $40.25 million in debt, resulting in a debt-to-equity ratio of 42.84, which signifies a highly leveraged position where debt obligations exceed equity significantly, though the absolute cash balance provides a buffer against interest payments. Liquidity is supported by a current ratio of 1.70, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Furthermore, the return on equity stands at -28.3% and the return on assets is -3.9%, metrics that collectively reveal that management has not yet generated returns on the capital deployed, as the company is currently operating at a loss on an equity and asset basis.
Waarderingsbeoordeling
Valuation metrics for Assertio Holdings present a complex picture given its lack of traditional earnings, with a trailing twelve-month P/E ratio listed as N/A due to negative net income, while the forward P/E is calculated at 6.96, suggesting that the market prices in anticipated future earnings growth that would lower the multiple over time. The price-to-book ratio is 1.23, indicating that the market values the company at a slight premium over its book value, which is typical for firms with intangible assets like intellectual property in the pharmaceutical sector. Alternative valuation measures include a price-to-sales ratio of 0.98 and an EV/EBITDA of 7.28, suggesting that the stock trades at roughly one dollar of sales per share and that the enterprise value relative to earnings before interest, taxes, depreciation, and amortization is moderate compared to the high-risk profile of a small-cap biotech or generic drug firm. Price action over the past year shows a 52-week high of $20.45 and a 52-week low of $8.55, meaning the current trading price sits within a wide range of volatility, specifically trading at approximately 41.5% below the 52-week high based on the available data points. The beta of 0.43 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may act as a defensive position or move less aggressively than large-cap equities during market swings.
Growth & Income
The growth profile is defined by a year-over-year revenue decline of -57.9%, while earnings growth is marked as N/A due to the negative net income, implying that the company is currently in a contraction phase regarding sales volume or is repositioning its product mix. The substantial drop in revenue suggests a challenging environment for the company's core products or a reduction in market share, and without positive earnings growth to offset this, the financial trajectory relies heavily on non-operating factors or cost reductions to stabilize. Regarding income, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is retained within the business to fund operations, R&D, or debt reduction rather than being distributed to shareholders. This reinvestment strategy is characteristic of companies in the development or restructuring phase that prioritize survival and future growth potential over immediate shareholder returns. Overall, the growth and income profile of Assertio Holdings is currently characterized by revenue contraction and a lack of dividend income, relying entirely on operational efficiency improvements and potential new product approvals to reverse the negative growth trends and restore profitability.